Objectives: The SMART (Study for Monitoring Antimicrobial Resistance Trends) surveillance programme was begun in 2002 to monitor antimicrobial resistance trends among aerobic and facultative Gram-negative bacilli (GNB) isolated from intra-abdominal infections worldwide.
Introduction
With emergence of antimicrobial resistance in bacteria as a global problem, national and international surveillance programmes have been developed to monitor resistance. [1] [2] [3] [4] [5] These studies serve not only to report point prevalence of resistance, but to detect potential resistance trends over time and may provide guidance in choosing empirical antimicrobial therapy for selected infections. The Study for Monitoring Antimicrobial Resistance Trends (SMART) was begun in 2002, and is the only global surveillance programme designed to monitor longitudinally the in vitro antimicrobial susceptibility of aerobic and facultative Gram-negative bacilli (GNB) isolated exclusively from intraabdominal sites. This report provides an overview of the results from January to December 2003, the first full year of the study. Acceptable specimens included tissue, fluid or deep wound cultures obtained intraoperatively, and fluid from paracentesis or percutaneous aspiration of abscesses. By protocol, duplicate isolates (the same genus and species from the same patient) were excluded, regardless of the elapsed time between procurement of the specimens and differences in antimicrobial susceptibilities. Isolates obtained from abdominal drains or drainage bottles, stool, superficial wounds, or perirectal abscesses were excluded. Bacteria were identified by standard methods used in the participating clinical microbiology laboratories. Organisms were divided into those isolated within <48 h of hospitalization and those isolated > _ 48 h after hospitalization. Custom-made microtitre trays (Dade Microscan, Inc., Sacramento, CA, USA) were shipped to each participating study centre for susceptibility testing. Antimicrobial susceptibility testing was performed using broth microdilution according to guidelines for MIC testing from the National Committee for Clinical Laboratory Standards.
Materials and methods

Seventy
6
Susceptibility was based on NCCLS breakpoints. 7 Twelve antimicrobial agents used to treat intraabdominal infections were tested: ertapenem, imipenem, meropenem, ceftriaxone, ceftazidime, cefoxitin, cefepime, piperacillin/ tazobactam, amikacin, tobramycin, ciprofloxacin and levofloxacin. Reference strains Escherichia coli ATCC 25922 and Pseudomonas aeruginosa ATCC 27853 were used as quality control strains for each batch of MIC tests, and were shipped to each laboratory if the strains were not available at the study site. MIC testing was repeated if results for ATCC strains were outside the expected range recommended by the NCCLS. Phenotypic identification of extendedspectrum b-lactamase (ESBL) production was expanded to include E. coli, Klebsiella spp. and Enterobacter spp., and was performed using a modification of the NCCLS method.
7 If the ceftazidime, ceftriaxone, or cefepime MIC was > _ 2 mg/L, then the MIC of cefepime was compared with the MIC of cefepime + clavulanic acid (10 mg). ESBL production was defined as > _ 8-fold decrease in the MIC for cefepime when tested in combination with clavulanic acid versus the cefepime MIC when tested in the absence of clavulanic acid. E. coli, Klebsiella spp. and Enterobacter spp. confirmed phenotypically to produce ESBLs were designated as resistant to ceftazidime, ceftriaxone and cefepime regardless of whether their MICs were within the NCCLS breakpoint for susceptibility.
Results
A total of 5658 aerobic and facultative Gram-negative bacilli were isolated from intra-abdominal infections in 4838 patients from the 74 participating study centres worldwide in 2003. Susceptibility results for the most frequently isolated organisms (> _ 1.0% of total isolates) are presented in Table 1 .
Enterobacteriaceae
Enterobacteriaceae composed 84% (4766/5658) of the total isolates, with Escherichia coli (46%; 2620/5658), Klebsiella spp. (17%; 971/5658) and Enterobacter spp. (8%; 471/5658) the most commonly isolated. Organisms in these three categories accounted for 72% (4062/5658) of all isolates and 85% (4062/4766) of Enterobacteriaceae isolated. Among the antimicrobial agents tested, the three carbapenems ertapenem, imipenem and meropenem were overall the most consistently active in vitro against the Enterobacteriaceae (Table 1 ). (Table 3 ). Ciprofloxacin and levofloxacin were the least active agents in all regions, with the lowest activity seen in Asia/Pacific (70.3% and 72.6% susceptible, respectively) ( Table 2 ). The MIC 90 s of ciprofloxacin and levofloxacin were > 4 and 8 mg/L, respectively.
Overall, E. coli isolated <48 h after hospitalization were more often susceptible to the agents tested than E. coli isolated > _ 48 h after hospitalization (Table 4 ). There was essentially no difference in percentage susceptibility between these two groups of E. coli for the carbapenems, but there were appreciable differences for the other agents tested, especially ciprofloxacin (83.6% susceptible versus 71.8% susceptible) and levofloxacin (84.5% susceptible versus 74.5% susceptible).
Klebsiella spp. Table 5 shows the susceptibility of Klebsiella spp. to 12 antimicrobial agents in the five broad geographic regions of Asia/Pacific, Europe, Latin America, USA and the Middle East. Klebsiella pneumoniae was the most common species isolated (72%), followed by Klebsiella oxytoca (20%), Klebsiella ozaenae (1%) and Klebsiella ornithinolytica (0.3%). Approximately 7% (65/971) of Klebsiella spp. were not identified to the species level. Ertapenem, imipenem and meropenem were again the most consistently active agents in all regions ( Table 5 ). The MIC 90 results for K. pneumoniae and K. oxytoca are shown in Table 3 . Overall, Klebsiella spp. isolated <48 h after hospitalization were more likely to be susceptible to the agents tested than Klebsiella spp. isolated > _ 48 h after hospitalization (Table 4 ). There was essentially no difference in percentage susceptibility between these two groups of Klebsiella spp. for the carbapenems, but there were perceptible differences for all the other agents tested (Table 4) .
Enterobacter spp. The susceptibility of Enterobacter spp. worldwide to 12 antimicrobial agents is shown in Table 1 . Enterobacter cloacae was the most common species isolated (72%), followed by Enterobacter aerogenes (16%), Enterobacter asburiae (0.4%), Enterobacter gergoviae (0.4%), Enterobacter sakazakii (0.4%), Enterobacter amnigenus (0.2%), Enterobacter intermedius (0.2%) and Enterobacter cancerogenus (0.2%). Approximately 9% (44/471) of Enterobacter spp. were not identified to the species level. Enterobacter spp. isolated <48 h after hospitalization were generally more likely to be susceptible to the agents tested than Enterobacter spp. isolated > _ 48 h after hospitalization (Table 4) .
ESBL production. Extended-spectrum b-lactamase production was screen test positive versus confirmed positive in 13% versus 9% (235/2620) of E. coli, 18% versus 14% (133/971) of Klebsiella spp. (with similar frequency in K. pneumoniae and K. oxytoca), and 50% versus 14% (68/471) of Enterobacter spp.
(16% E. cloacae and 12% E. aerogenes confirmed positive). The prevalence of confirmed ESBL-positive isolates in the USA, Europe, Latin America, the Middle East and Asia/Pacific among E. coli was 3%, 5%, 10%, 13% and 17%, among Klebsiella spp. was 7%, 11%, 14%, 20% and 18%, and among Enterobacter spp. was 16%, 7%, 20%, 12% and 21%, respectively. Overall, ESBLs were detected less frequently in organisms isolated <48 h after hospitalization than in organisms isolated > _ 48 h after hospitalization among E. coli (5% versus 13%), Klebsiella spp. (8% versus 19%), and Enterobacter spp. (9% versus 17%). When the percentage susceptibilities of ESBL and non-ESBL producers were compared, the differences in susceptibility to ertapenem, imipenem and meropenem were generally small between the two groups, whereas the differences in susceptibility to the other agents tested were typically much greater (Table 6 ).
Non-fermentative and fermentative non-Enterobacteriaceae
Non-Enterobacteriaceae comprised 16% (892/5658) of all isolates in the study. Pseudomonas aeruginosa was the most common non-fermentative GNB isolated, comprising 11% (605/5658) of the total isolates. Thirty-two percent of P. aeruginosa were isolated <48 h after hospitalization and 68% were isolated > _ 48 h after hospitalization. Among the anti-pseudomonal agents tested, piperacillin/tazobactam (90.9% susceptible) and amikacin (90.1% susceptible) were the most frequently active agents, whereas ciprofloxacin and levofloxacin exhibited the lowest activity (77.0% and 77.2% susceptible, respectively) ( Tables 1 and 7) . For all the agents tested, P. aeruginosa isolated earlier were more susceptible than those isolated later in the hospitalization (Table 4) .
Acinetobacter baumannii was the second most commonly isolated non-fermentative GNB, but comprised just 1.5% (84/5658) of all isolates. Eighty-five percent (71/84) of A. baumannii were isolated > _ 48 h after hospitalization. Imipenem was the most active agent against A. baumannii (64.3% susceptible), followed by meropenem (53.6% susceptible). All other agents tested exhibited much less consistent activity against A. baumannii (range 22.6% to 41.7% susceptible; Table 1 ).
Discussion
Emerging bacterial resistance remains a concern worldwide. 8 Ongoing antimicrobial surveillance studies may reveal resistance trends over time, and may potentially help to guide the selection of empirical therapy in select clinical settings. Includes 65 Klebsiella that were not identified to the species level and 14 speciated, non-pneumoniae/non-oxytoca Klebsiella.
c Includes 44 Enterobacter that were not identified to the species level and 9 speciated, non-cloacae/non-aerogenes Enterobacter.
E. coli was by far the most common isolate in our study (46% of all isolates). The lower susceptibility rate of E. coli to ciprofloxacin and levofloxacin compared with the other agents tested was consistent in all geographic regions worldwide, but particularly outside the USA (Table 2) . Consequently, whether quinolones should remain among the first line choices for empirical therapy of complicated intra-abdominal infections 9, 10 in some geographic regions may be open for further discussion. Although E. coli isolated <48 h after admission to hospital (and presumed to be community-acquired) were more susceptible to ciprofloxacin and levofloxacin than those isolated > _ 48 h after hospitalization, all the other agents tested still had more reliable activity against this subgroup of isolates (Table 4) . While clinical outcomes may not always reflect in vitro susceptibility results in intra-abdominal infections where surgical drainage has a major impact, results of surveillance data may still provide useful guidance in selecting empirical antimicrobial therapy for some patients, especially given that intra-operative cultures are not routinely obtained at initial intervention in these patients.
Enterobacteriaceae as expected were the most commonly isolated aerobic GNB in intra-abdominal infections, and were the most consistently susceptible to the carbapenems. While the susceptibility of E. coli and Klebsiella spp. to the carbapenems did not vary among the five geographic regions, susceptibility to the other agents tested often varied by region, with susceptibility rates generally lowest in Asia/Pacific, Latin America and the Middle East (Tables 2 and 5 ). Not surprisingly, organisms isolated > _ 48 h after hospitalization were in general more often resistant than those isolated <48 h after hospitalization ( Table 5 ), except that E. coli, Klebsiella spp. and Enterobacter spp. remained consistently susceptible to the carbapenems regardless of when the cultures were obtained.
The division of cultures into those performed <48 h versus > _ 48 h after hospitalization was intended to separate organisms acquired in the community from those acquired in a hospital setting. This division, based solely on time of culture, has its limitations. For example, an isolate obtained <48 h after hospitalization in a patient recently discharged from hospital MIC breakpoints for ertapenem and cefoxitin in non-Enterobacteriaceae have not been defined by the NCCLS. b The 95% exact binomial confidence intervals (CI) are presented for the difference calculated as the % susceptible rate for isolates obtained < 48 h after hospitalization minus the % susceptible rate for isolates obtained > _ 48 h after hospitalization.
may not have been truly 'community-acquired', and an isolate from an outpatient admitted with an intra-abdominal infection that was cultured > _ 48 h after hospitalization may not have been truly 'hospital-acquired'. Nonetheless, these results are consistent with the concept that isolates acquired in the hospital are generally more resistant than those acquired in the community. The emergence of ESBLs among Enterobacteriaceae has made in vitro susceptibility testing more complicated since the The 95% exact binomial confidence intervals (CI) are presented for the difference calculated as the % susceptible rate for non-ESBL producers minus the % susceptible rate for ESBL producers.
MIC of some cephalosporins for certain ESBL producers can fall below the traditional NCCLS susceptibility breakpoint.
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ESBLs have been reported most commonly among E. coli and Klebsiella spp., but are now detected increasingly in other Enterobacteriaceae as well. 11 The current NCCLS guidelines for screening and confirming ESBL in E. coli, K. pneumoniae and K. oxytoca may not be appropriate for testing Enterobacteriaceae that possess the inducible ampC b-lactamase gene. 11, 12 One proposed solution is to include cefepime as a screening agent, as well as in the confirmatory test in combination with clavulanic acid.
12 -16 However, the use of cefepime as the only cephalosporin with clavulanic acid as the confirmatory ESBL test may have potentially resulted in under-reporting of the presence of ESBLs in this study. Our results confirm previous reports that ESBL-producing isolates are not merely confined to the hospital setting, but are increasingly isolated from the community.
17
There was a surprisingly high frequency of Enterobacter in our study that were identified as ESBL-producers (7 -21%). In particular areas of the world, this has been reported to be mainly due to the inter-country spread of Enterobacter clones producing TEM-24 or SHV-7. 18, 19 In any case, the high frequency of ESBL isolation in Enterobacteriaceae that was observed in some regions in our study is noteworthy, and suggests that third-and fourth-generation cephalosporins may not be an ideal choice in the empirical therapy of intra-abdominal infections in some geographic areas.
There remains some controversy as to whether phenotypic screening and confirmation tests for ESBL should be performed in Enterobacteriaceae other than the three species currently recommended by the NCCLS, E. coli, K. pneumoniae and K. oxytoca, since the prevalence of ESBL in other genera and species has been reported to be low in some studies. 11, 15, 20 In one study, 51% (355/690) of other Enterobacteriaceae (other than E. coli and Klebsiella spp.) were screen test positive for ESBL, but only 2% (15/690) were confirmed as ESBL producers using the NCCLS recommended method. 20 In the same study, 83% (126/152) of Enterobacter spp. were screen test positive, but only 2% (3/152) were confirmed to be ESBL producers using both cefotaxime and ceftazidime with clavulanate. 20 Enterobacter spp. were the third most common Enterobacteriaceae isolated in our study. While only 50% (234/471) of Enterobacter spp.
were screen test positive for ESBL, 14% (68/471) were confirmed as ESBL producers using cefepime + clavulanate. This result supports what has been suggested by others that cefepime + clavulanate may be useful in detecting ESBL production in Enterobacter spp. 11 -16 All surveillance studies have their limitations. 21, 22 Although the 2003 SMART study was global, it included only 74 study sites, and the distribution of sites in each geographic region was not always uniform, which largely reflected the ease of recruiting study sites in some countries as well as the difficulty with recruiting sites in other countries. Therefore, the results from any one country or region should be interpreted carefully. As with most surveillance studies, resistant isolates may be overrepresented as complicated patients who may have received multiple antibiotics might be sampled more frequently. Even so, this surveillance programme does provide a helpful overview of general antimicrobial resistance patterns among Gram-negative bacilli isolated from intra-abdominal infections worldwide, and will be continuing on an annual basis. 
